BriaCell Therapeutics Corp.BCTXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | -198.67% | +0.00% | -483.88% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -198.03% | +0.00% | -477.35% | +0.00% | +0.00% |
| EPS Growth | -158.80% | +0.00% | -207.61% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | -207.61% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +66.70% | +153.37% | +75.30% | +56.75% | +6.07% |
| Weighted Average Shares Diluted Growth | +59.77% | +153.37% | +75.30% | +56.75% | +6.07% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +11377.02% | +7716.27% | +15331.13% | -59.14% | -65.29% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -43.37% | -16.06% | +177.10% | +265.14% | -9.81% |
| Book Value per Share Growth | -9.77% | +0.00% | +0.00% | +0.00% | +67.16% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | -45.80% | -26.65% | -33.62% | +60.19% | +84.90% |
| SG&A Expenses Growth | -9.79% | -0.94% | +0.50% | +9.04% | -17.71% |